Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer

BACKGROUND: Programmed death‐ligand 1 (PD‐L1) is an important screening biomarker to select patients with gastric cancer (GC) for optimized treatment, including immune checkpoint inhibitors (ICI). METHODS: In this single‐institution retrospective cohort study, patients with metastatic GC with availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Minkyue, Ahn, Soomin, Jung, Jaeyun, Hyung, Sujin, Kim, Kyoung‐Mee, Kim, Seung Tae, Kang, Won Ki, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557860/
https://www.ncbi.nlm.nih.gov/pubmed/37654198
http://dx.doi.org/10.1002/cam4.6472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557860/
https://www.ncbi.nlm.nih.gov/pubmed/37654198
http://dx.doi.org/10.1002/cam4.6472

Ejemplares similares